ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia

被引：6
|
作者：
De Propris, Maria Stefania [1 ]
Intoppa, Stefania [1 ]
Milani, Maria Laura [1 ]
Mariglia, Paola [1 ]
Nardacci, Maria Grazia [1 ]
Peragine, Nadia [1 ]
Foa, Robin [1 ]
Guarini, Anna [1 ]
机构：
[1] Sapienza Univ, Dept Translat & Precis Med, Hematol, Rome, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 190卷 / 06期
关键词：
CLL; ROR1; MRD; progression disease; haematogones; RECEPTOR TYROSINE KINASE;
D O I：
10.1111/bjh.16910
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e346 / e349
页数：4
相关论文
共 50 条
  • [31] Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1
    Cui, Bing
    Widhopf, George F., II
    Yu, Jian
    Martinez, Daniel
    Avery, Esther
    Zhang, Suping
    Chen, Liguang
    Wu, Rongrong
    Wu, Christina C. N.
    Prussak, Charles
    Kipps, Thomas J.
    [J]. BLOOD, 2011, 118 (21) : 450 - 450
  • [32] Minimal residual disease in chronic myeloid leukaemia patients
    Hochhaus, A
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 159 - 178
  • [33] Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo
    Liu, Zhuojun
    Liu, Jia
    Zhang, Tianming
    Shi, Mingxia
    Chen, Xiaofang
    Chen, Yun
    Yu, Jian
    [J]. PHARMACOLOGICAL RESEARCH, 2020, 151
  • [34] Ovarian minimal residual disease in chronic myeloid leukaemia
    Abir, Ronit
    Aviram, Adina
    Feinmesser, Meora
    Stein, Jerry
    Yaniv, Isaac
    Parnes, Doris
    Ben-Haroush, Avi
    Meirow, Dror
    Rabizadeh, Esther
    Fisch, Benjamin
    [J]. REPRODUCTIVE BIOMEDICINE ONLINE, 2014, 28 (02) : 255 - 260
  • [35] Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia
    Lew, Thomas
    Anderson, Mary Ann
    Lin, Victor
    Handunnetti, Sasanka
    Came, Neil
    Westerman, David
    Meaghan, Wall
    Tam, Constantine
    Roberts, Andrew W.
    Seymour, John F.
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 : 172 - 174
  • [36] Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL
    Hayat, Amjad
    O'Brien, David
    Quinn, Fiona
    Keane, Fionnuala
    Parker, Imelda
    Kelly, Johanna
    Wieczorkowska, Marzena
    Crotty, Gerard
    Leahy, Maeve
    Enright, Helen
    Hennessy, Brian
    Cahill, Mary
    Vandenberghe, Elisabeth A.
    [J]. BLOOD, 2012, 120 (21)
  • [37] Assessing minimal residual disease in chronic lymphocytic leukemia
    Rawstron A.C.
    Hillmen P.
    [J]. Current Hematologic Malignancy Reports, 2008, 3 (1) : 47 - 53
  • [38] The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia
    Al-Sawaf, Othman
    Hallek, Michael
    Fischer, Kirsten
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 97 - 103
  • [39] Minimal residual disease assessment in chronic lymphocytic leukemia
    Maloum, Karim
    [J]. HEMATOLOGIE, 2006, 12 (04): : 274 - 281
  • [40] Eradication of minimal residual disease in chronic lymphocytic leukemia
    Schweighofer C.D.
    Hallek M.
    Wendtner C.-M.
    [J]. Current Hematologic Malignancy Reports, 2008, 3 (1) : 54 - 60
12345